In this webinar, we explain how Malvern and PANalytical’s unique range of physicochemical analysis techniques can be used to accelerate the development of oral solid dose products, reducing the time to market for new complex generics.

Oral solid dose (OSD) drug products represent the largest class of products sold by the pharmaceutical industry, and as a result represent a significant opportunity for generic companies. Within this, products which have a modified or sustained release profile represent a significant challenge, as deformulation of these requires specific knowledge of the physicochemical properties of the active pharmaceutical ingredient (API) and any functional excipients present within the formulation.

We’ll explain how the range of measurement solutions from Malvern and PANalytical enable critical material attributes such as particle size, shape, structure and composition to be measured, aiding deformulation and rapid formulation development for complex oral solid dose products.